Guttman-Yassky, E., Zhou, L. & Krueger, J. G. The skin as an immune organ: tolerance versus effector responses and applications to food allergy and hypersensitivity reactions. J. Allergy Clin. Immunol. 144, 362–374 (2019).
Article CAS PubMed Google Scholar
Clark, R. A. et al. The vast majority of CLA+ T cells are resident in normal skin. J. Immunol. 176, 4431–4439 (2006).
Article CAS PubMed Google Scholar
Vu, T. T., Koguchi-Yoshioka, H. & Watanabe, R. Skin-resident memory T cells: pathogenesis and implication for the treatment of psoriasis. J. Clin. Med. 10, 3822 (2021).
Article CAS PubMed PubMed Central Google Scholar
Tamari, M., Ver Heul, A. M. & Kim, B. S. Immunosensation: neuroimmune cross talk in the skin. Annu. Rev. Immunol. 39, 369–393 (2021).
Article CAS PubMed Google Scholar
Charkoudian, N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin. Proc. 78, 603–612 (2003).
Kim, B. et al. Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms, and therapeutic targets in atopic diseases. J. Allergy Clin. Immunol. 153, 879–893 (2023).
Article PubMed PubMed Central Google Scholar
Johnson, K. E. & Wilgus, T. A. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv. Wound Care 3, 647–661 (2014).
Feingold, K. R. The outer frontier: the importance of lipid metabolism in the skin. J. Lipid Res. 50, S417–S422 (2009).
Article PubMed PubMed Central Google Scholar
Jara, C. P., Mendes, N. F., do Prado, T. P. & de Araujo, E. P. Bioactive fatty acids in the resolution of chronic inflammation in skin wounds. Adv. Wound Care (N. Rochelle) 9, 472–490 (2020).
Bertola, E. A. et al. Extrarenal immune-mediated disorders linked with acute poststreptococcal glomerulonephritis: a systematic review. Clin. Rev. Allergy Immunol. 57, 294–302 (2019).
Article CAS PubMed Google Scholar
Muhamed, B., Parks, T. & Sliwa, K. Genetics of rheumatic fever and rheumatic heart disease. Nat. Rev. Cardiol. 17, 145–154 (2020).
Carapetis, J. R. et al. Acute rheumatic fever and rheumatic heart disease. Nat. Rev. Dis. Prim. 2, 15084 (2016).
Piette, W. W. in Fitzpatrick’s Dermatology 9th edn Ch. 66 (eds Kang, S. et al.) (McGraw-Hill, 2019).
D’Aguanno, V. et al. Systemic amyloidosis: a contemporary overview. Clin. Rev. Allergy Immunol. 59, 304–322 (2020).
Merlini, G., Seldin, D. C. & Gertz, M. A. Amyloidosis: pathogenesis and new therapeutic options. J. Clin. Oncol. 29, 1924–1933 (2011).
Article PubMed PubMed Central Google Scholar
Horvath, A. & Stratakis, C. A. Carney complex and lentiginosis. Pigment. Cell Melanoma Res. 22, 580–587 (2009).
Article CAS PubMed PubMed Central Google Scholar
Pitsava, G., Zhu, C., Sundaram, R., Mills, J. L. & Stratakis, C. A. Predicting the risk of cardiac myxoma in Carney complex. Genet. Med. 23, 80–85 (2021).
Article CAS PubMed Google Scholar
Malfait, F. et al. The Ehlers–Danlos syndromes. Nat. Rev. Dis. Prim. 6, 64 (2020).
Zilocchi, M. et al. Vascular Ehlers–Danlos syndrome: imaging findings. AJR Am. J. Roentgenol. 189, 712–719 (2007).
Shabani, M. et al. Vascular aneurysms in Ehlers–Danlos syndrome subtypes: a systematic review. Clin. Genet. 103, 261–267 (2023).
Article CAS PubMed Google Scholar
D’Hondt, S., Van Damme, T. & Malfait, F. Vascular phenotypes in nonvascular subtypes of the Ehlers–Danlos syndrome: a systematic review. Genet. Med. 20, 562–573 (2018).
van de Laar, I. et al. Surveillance and monitoring in vascular Ehlers–Danlos syndrome in European Reference Network For Rare Vascular Diseases (VASCERN). Eur. J. Med. Genet. 65, 104557 (2022).
Ong, K. T. et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet 376, 1476–1484 (2010).
Article CAS PubMed Google Scholar
Frank, M. et al. Vascular Ehlers–Danlos syndrome: long-term observational study. J. Am. Coll. Cardiol. 73, 1948–1957 (2019).
Baderkhan, H., Wanhainen, A., Stenborg, A., Stattin, E. L. & Bjorck, M. Celiprolol treatment in patients with vascular Ehlers–Danlos syndrome. Eur. J. Vasc. Endovasc. Surg. 61, 326–331 (2021).
De Backer, J. & De Backer, T. Vascular Ehlers–Danlos syndrome management: the Paris way, a step forward on a long road. J. Am. Coll. Cardiol. 73, 1958–1960 (2019).
Murdoch, D. R. et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch. Intern. Med. 169, 463–473 (2009).
Article PubMed PubMed Central Google Scholar
Habib, G. et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European Infective Endocarditis) registry: a prospective cohort study. Eur. Heart J. 40, 3222–3232 (2019).
McCrindle, B. W. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135, e927–e999 (2017).
Noval Rivas, M. & Arditi, M. Kawasaki disease: pathophysiology and insights from mouse models. Nat. Rev. Rheumatol. 16, 391–405 (2020).
Article PubMed PubMed Central Google Scholar
Watanabe, Y., Ikeda, H. & Watanabe, T. Differences in the clinical characteristics of Kawasaki disease between older and younger children (2015-2019): a single-center, retrospective study. J. Pediatr. 253, 266–269 (2023).
Saundankar, J. et al. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics 133, e1009–e1014 (2014).
Sanchez-Manubens, J., Bou, R. & Anton, J. Diagnosis and classification of Kawasaki disease. J. Autoimmun. 48-49, 113–117 (2014).
Article CAS PubMed Google Scholar
Rowley, A. H. in Fitzpatrick’s Dermatology 9th edn Ch. 142 (eds Kang, S. et al.) (McGraw-Hill, 2019).
Fukazawa, R. et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ. J. 84, 1348–1407 (2020).
Article CAS PubMed Google Scholar
Green, J., Wardle, A. J. & Tulloh, R. M. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst. Rev. 5, CD011188 (2022).
Kabbaha, S., Milano, A., Aldeyab, M. A. & Thorlund, K. Infliximab as a second-line therapy for children with refractory
Comments (0)